研究成果 |
首次发现真性红细胞增多症患者体内存在酪氨酸激酶JAK2V617F突变，最先应用JAK2V617F转基因小鼠模型证明了JAK2V617F是导致骨髓增殖性肿瘤的原因。以蛋白质酪氨酸激酶和磷酸酶为靶标，先后从中草药、有机和无机金属配合物中筛选到20余种极具临床应用前景的治疗2型糖尿病、癌症、免疫缺陷等人类重大疾病的抑制剂。 近年来，申请人先后主持和参与科研课题10余项，发表SCI收录的论文40余篇，获得吉林省自然科学奖一等奖1次（2015年，第二完成人）、吉林省科技进步奖一等奖1次（2010，第三完成人）、中华医学科技奖三等奖1次（2014年，第二完成人）。 代表性论文（近5年）： 1. Cui H, Fu X, Yang L,Xing S*, Wang X*. 2D Titanium Carbide Nanosheets Based Fluorescent Aptasensor for Sensitive Detection of Thrombin.Talanta. 2021, 228: 122219. 2. Chen X, Fu X, Zhao W, Ho WT,Xing S*, Zhao ZJ*. Loss of tyrosine phosphatase SHP2 activity promotes growth of colorectal carcinoma HCT-116 cells.Signal Transduct Target Ther.2020, 5(1): 83-85. 3. Yuan C, Wang W, Wang J, Li X, Wu YB, Li S, Lu L*, Zhu M*,Xing S*, Fu X. Potent and selective PTP1B inhibition by a platinum(ii) complex: possible implications for a new antitumor strategy.Chem Commun (Camb). 2019, 56(1): 102-105. 4. Lin L, Lu L*, Du R, Yuan C, Zhu M*, Fu X,Xing S*. A Ce(iii) complex potently inhibits the activity and expression of tyrosine phosphatase SHP-2.Dalton Trans.2019, 48(47): 17673-17682. 5. Wang L, Wei B, Fu X, Wang Y, Sui Y, Ma J, Gong X, Hao J*,Xing S*. Identification of whirlin domains interacting with espin: A study of the mechanism of Usher syndrome type II.Mol Med Rep. 2019, 20(6): 5111-5117. 6. Sui Y, Fu X, Wang Y, Hu W, Zhang T, Liu W, Jiang L,Xing S*, Fu X*. Xu X*.Expression, purification and characterization of a catalytic domain of human protein tyrosine phosphatase non-receptor 12 (PTPN12) in Escherichia coli with FKBP-type PPIase as a chaperon.Protein Expr Purif. 2018, 142: 45-52. 7. Jia Y, Lu L*, Zhu M*, Yuan C,Xing S*, Fu X. A dioxidovanadium (V) complex of NNO-donor Schiff base as a selective inhibitor of protein tyrosine phosphatase 1B: Synthesis, characterization, and biological activities.Eur J Med Chem. 2017, 128:287-292. |
